The analgesic effect of intravenous indoprofen and lysine acetylsalicylate in patients with postoperative pain

A study of the analgesic potency of indoprofen and pentazocine in postoperative pain

The relative potency of intravenous indoprofen and intramuscular pentazocine in postoperative pain was evaluated. Indoprofen was administered in 200- and 400-mg single doses and pentazocine was given in 15- and 30-mg doses. Pain was assessed at different time intervals, and additional medication consumption was recorded, as well as side effects and overall evaluations. An analysis of peak pain intensity difference (PID) has shown a significant dose-effect relationship for both drugs and a potency ratio of 1:7 between indoprofen and pentazocine (mg to mg). Based on the frequency of patients requiring remedication and those reporting total pain relief in at least one instance, the potency ratio of indoprofen:pentazocine was 1:13 and 1:10, respectively. The mean peak PID of the pooled data for both doses of each drug was significantly greater for indoprofen. Intravenous indoprofen 400 mg was ranked the most effective overall.

Indoprofen and pentazocine in post-traumatic pain. A double-blind, parallel-group comparative trial

In a double-blind, randomized, parallel-group study involving sixty patients with severe pain due to fractures, the analgesic activity of indoprofen and pentazocine was evaluated. Each patient received one of the following treatments in random order: indoprofen 400 mg i.v., pentazocine 30 mg i.v., placebo. The analgesic effect was measured by rating the intensity of pain before treatment and after 1/2, 1, 2, 4 and 6 hours. Patients' final opinions on efficacy were assessed on the basis of categoric and visual analogue scales. Highly significant differences were found between the active drugs and placebo for all variables analyzed. Indoprofen was significantly superior to pentazocine when assessed through variables measuring total analgesic effects. Since both drugs were well tolerated, i.v. indoprofen appears to offer an effective and safe alternative to narcotic analgesics in acute pain due to fractures.

Inhibition of the cardiovascular effects of lysine acetylsalicylate by propranolol in dogs during halothane anaesthesia

The cardiovascular effects of lysine acetylsalicylate and/or propranolol were studied in 26 dogs. All animals were maintained under anaesthesia with halothane 0.75 per cent, supplemented by the intravenous administration of succinylcholine to allow controlled ventilation during a two hour period of monitoring. Cardiac output, stroke volume, heart rate, mean arterial pressure, pulse pressure, central venous pressure, total peripheral resistance, pH, Paco2, pao2 and base deficit were measured in each dog. Lysine acetylsalicylate 50 mg . kg-1, administered alone as a single bolus, significantly (P less than 0.05) increased the cardiac output and stroke volume and significantly decreased the heart rate, central venous pressure and total peripheral resistance in dogs under halothane anaesthesia. Propranolol hydrochloride 0.5 mg . kg-1 as a single intravenous bolus was followed by a significant decrease in cardiac output, heart rate and mean arterial pressure and a significant increase in central venous pressure and total peripheral resistance. The administration of propranolol prior to lysine acetylsalicylate resulted in a significant decrease in cardiac output and heart rate. Pretreatment with propranolol was effective in inhibiting the positive inotropic effect of lysine acetylsalicylate.

Effects of intravenous indoprofen on bleeding time and other haemostatic parameters

The influence of i.v. administration of indoprofen on template bleeding time and other haemostatic parameters was investigated in ten elderly subjects with osteoarthritis. The drug was given first as a single dose (400 mg bolus) and then, after an appropriate interval, as a short-term treatment (200 mg bolus t.i.d. for 7 days). Platelet count, prothrombin time and partial thromboplastin time were never affected, whereas a significant, though moderate, lengthening of bleeding time and a parallel reduction of platelet aggregation were observed in both trials. In the acute one these changes were seen at the first hour following administration and waned in all patients within 96 hours. In the subacute test the bleeding time was steadily prolonged throughout the week of treatment, being slightly still above the baseline value 7 days later, at which time no residual effects were noticeable in platelet aggregation.